NCT04451187 - A Study of Oral Seltorexant as an add-on Medication to an Antidepressant on On-road Driving Performance in Participants With Major Depressive Disorder | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 16, 2020

Primary Completion Date

March 16, 2023

Study Completion Date

March 16, 2023

Conditions

Depressive Disorder, Major

Interventions

DRUG

Seltorexant Dose 1

Participants will receive Dose 1 of seltorexant OD from Day 1 to Day 8 as part of Treatment A as per assigned treatment sequence.

DRUG

Seltorexant Dose 2

Participants will receive Dose 2 of seltorexant OD from Day 1 to Day 8 as part of Treatment D as per assigned treatment sequence.

DRUG

Placebo

Participants will receive placebo of seltorexant OD from Day 1 to Day 8 as a part of Treatment A and C and from Day 2 and Day 7 as a part of Treatment B as per assigned treatment sequence.

DRUG

Zopiclone

Participants will receive Dose 3 of zopiclone OD from Day 1 to Day 8 as a part of Treatment B as per assigned treatment sequence.

Trial Locations (2)

3570

Anima, Alken

52074

Universitaetsklinikum der RWTH Aachen, Aachen

All Listed Sponsors

lead

Janssen Research & Development, LLC

INDUSTRY